Envoy Medical, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 28, 2025, regarding Envoy Medical, Inc.'s 2025 Annual Meeting of Stockholders. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in White Bear Lake, MN. Its Class A Common Stock (COCH) and Redeemable Warrants (COCHW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Corporate Actions
The primary material change reported is the stockholder approval of an amendment to the Company's 2023 Equity Incentive Plan. This amendment removes a restriction on 1,500,000 shares of common stock that were previously unavailable for issuance until a regulatory milestone was achieved. The amendment became effective immediately upon stockholder approval.
Voting Results and Governance
At the Annual Meeting, stockholders voted on four matters with the following results:
- Election of Directors: Two Class II director nominees were elected:
- Janis Smith-Gomez: 12,636,087 For; 375,248 Withheld.
- Chuck Brynelsen: 12,307,953 For; 703,382 Withheld.
- Ratification of Auditors: Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025 (13,031,300 For; 9,124 Against).
- Executive Compensation: Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers (12,771,564 For; 237,266 Against).
- Equity Plan Amendment: Stockholders approved the amendment to the 2023 Equity Incentive Plan (12,332,451 For; 658,102 Against).
Outlook, Risks, and Contingencies
The filing does not contain updated guidance, management commentary on future outlook, or new risk factors. The removal of the regulatory milestone restriction on the 1,500,000 shares implies that the Company may have achieved the necessary regulatory status or decided to proceed without it, though the specific regulatory context is detailed in the definitive proxy statement filed on April 18, 2025.
Key Facts for Investor Verification
- Verify the specific regulatory milestone that was previously required for the 1,500,000 shares to determine if it has been met or waived.
- Review the definitive proxy statement (filed April 18, 2025) for detailed terms of the amended 2023 Equity Incentive Plan.
- Confirm the total number of shares authorized for issuance under the 2023 Plan post-amendment to assess potential dilution.
- Check the Company's latest 10-K or 10-Q for financial health metrics not included in this 8-K.